STOCK TITAN
  1. Home
  2. News
  3. LLY

Eli Lilly & Co. - LLY STOCK NEWS

Welcome to our dedicated page for Eli Lilly & Co. news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Eli Lilly & Co. stock.

Eli Lilly and Company (NYSE: LLY), founded in 1876 by Colonel Eli Lilly, is a global leader in the pharmaceutical industry, headquartered in Indianapolis, Indiana. With operations in 18 countries and products sold in approximately 125 countries, Eli Lilly is dedicated to pioneering life-changing discoveries through innovative drug development. The company focuses on several therapeutic areas including neuroscience, cardiometabolic, cancer, and immunology.

Key products in Eli Lilly’s portfolio include Verzenio for cancer treatment; Jardiance, Trulicity, Humalog, Humulin, Mounjaro, and Zepbound for diabetes management; and Taltz and Olumiant for immunology. The company's recent financial performance has been robust, with Q1 2024 revenues increasing by 26% year-over-year to $8.77 billion, driven by strong sales of Mounjaro and Zepbound.

Eli Lilly continues to expand its manufacturing capabilities to meet growing demand, recently investing $5.3 billion in its Lebanon, Indiana site. This commitment supports the production of key therapies, particularly for chronic diseases like obesity and type 2 diabetes. The company’s innovative endeavors include the development of new treatments such as the once-weekly insulin efsitora alfa, which showed promising results in phase 3 trials for type 2 diabetes.

The company is also advancing its pipeline of oncology treatments with presentations of data on products like Verzenio, Retevmo, olomorasib, and imlunestrant at major medical conferences. Furthermore, Eli Lilly announced a major leadership change with Melissa Seymour joining as Executive Vice President of Global Quality, ensuring the sustained excellence of their product offerings.

Eli Lilly’s commitment to addressing significant health challenges is evident in its diverse product pipeline and ongoing clinical trials. The company remains focused on improving patient outcomes globally by harnessing advancements in biotechnology, chemistry, and genetic medicine.

News

Jardiance® (empagliflozin) approved in the EU for the treatment of adults with chronic kidney disease

Rhea-AI Summary
LLY: Jardiance Approved by European Commission for Chronic Kidney Disease Treatment - Boehringer Ingelheim and Eli Lilly announce the approval of Jardiance for the treatment of chronic kidney disease by the European Commission. The approval is based on the results from EMPA-KIDNEY, which showed a significant benefit of empagliflozin in reducing the relative risk of kidney disease progression or cardiovascular death by 28 percent vs. placebo in people with CKD. With existing indications in type 2 diabetes and heart failure, empagliflozin could help manage the risks of cardio-renal-metabolic conditions, which are often interconnected.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
none
-
News

Lilly Announces Extension of Tender Offer to Acquire DICE

Rhea-AI Summary
Eli Lilly and Company has extended the expiration of the tender offer to acquire all of the issued and outstanding shares of DICE Therapeutics, Inc. The purchase price is $48 per share in cash. The tender offer has been extended until August 8, 2023. Approximately 20.05% of the shares have been tendered as of July 24, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
acquisition
-
News

Results from Lilly's Landmark Phase 3 Trial of Donanemab Presented at Alzheimer's Association Conference and Published in JAMA

Rhea-AI Summary
Eli Lilly and Company presented full results from the Phase 3 TRAILBLAZER-ALZ 2 study, showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer's disease. The study demonstrated a 35% decline in participants with low-medium levels of tau and a 22% decline in all amyloid-positive early symptomatic AD participants. The treatment effect of donanemab continued to grow throughout the trial. FDA submission was completed in Q2, with regulatory action expected by the end of the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
clinical trial
News

Medicxi asset-centric portfolio company Versanis Bio to be acquired by Lilly to improve patient outcomes in cardiometabolic diseases

Rhea-AI Summary
Medicxi (NYSE: LLY) announces the acquisition of its portfolio company, Versanis Bio, by Eli Lilly and Company for up to $1.925 billion USD in cash. Versanis is focused on developing new medicines for cardiometabolic diseases, with its lead asset, bimagrumab, currently being assessed in a Phase 2b study for the treatment of overweight or obesity. This acquisition reinforces Medicxi's commitment to investing in asset-driven companies and its belief in the therapeutic potential of bimagrumab in improving patient outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.4%
Tags
acquisition
-
News

Lilly to Acquire Versanis to Improve Patient Outcomes in Cardiometabolic Diseases

Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) to Acquire Versanis Bio, a Clinical-Stage Biopharmaceutical Company, for Development of New Medicines for Cardiometabolic Diseases. Lead asset is bimagrumab, a monoclonal antibody currently being assessed in the BELIEVE Phase 2b study alone and in combination with semaglutide in adults who are overweight or obese. Agreement includes potential $1.925 billion in cash for Versanis shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.4%
Tags
acquisition
-
News

Lilly Announces Webcast to Provide Alzheimer's Disease Update at AAIC

Rhea-AI Summary
Eli Lilly and Company will host a webcast on July 17, 2023 at the Alzheimer's Association International Conference. The webcast will focus on results from the donanemab TRAILBLAZER-ALZ 2 clinical trial and the broader landscape in Alzheimer's disease. A live audio webcast will be available on Lilly's Investor website and a replay will be available for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.04%
Tags
none
News

RemeGen and Innovent Collaborate on Clinical Trials to Evaluate the Potential of RC88 and RC108 Combined with PD-1 Therapy for Advanced Solid Tumors

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.24%
Tags
clinical trial
-
News

New England Journal of Medicine Publishes BRUIN Phase 1/2 Trial Data for Pirtobrutinib in BTK Inhibitor Pre-Treated Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.53%
Tags
clinical trial
-
News

Lilly to Acquire Sigilon Therapeutics

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.26%
Tags
acquisition
News

Lilly's phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight

Rhea-AI Summary
Eli Lilly and Company announced phase 2 data for retatrutide, their investigational molecule for the treatment of obesity. The primary endpoint was met with a mean weight reduction of up to 17.5% at 24 weeks. In a secondary endpoint, retatrutide demonstrated a mean weight reduction of up to 24.2% at 48 weeks. The safety profile was similar to other therapies, with gastrointestinal side effects being the most commonly reported. The results were presented at the American Diabetes Association's 83rd Scientific Sessions and published in The New England Journal of Medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.59%
Tags
clinical trial

FAQ

What is the current stock price of Eli Lilly & Co. (LLY)?

The current stock price of Eli Lilly & Co. (LLY) is $746.2 as of November 15, 2024.

What is the market cap of Eli Lilly & Co. (LLY)?

The market cap of Eli Lilly & Co. (LLY) is approximately 713.4B.

What are Eli Lilly's core business areas?

Eli Lilly focuses on neuroscience, cardiometabolic, cancer, and immunology.

What are some of Eli Lilly's key products?

Key products include Verzenio for cancer, Jardiance, Trulicity, Humalog, Humulin, Mounjaro, and Zepbound for diabetes, and Taltz and Olumiant for immunology.

How did Eli Lilly perform financially in Q1 2024?

Eli Lilly reported a 26% year-over-year increase in revenue to $8.77 billion, driven by strong sales of Mounjaro and Zepbound.

What recent investments has Eli Lilly made?

Eli Lilly has invested $5.3 billion to expand its manufacturing site in Lebanon, Indiana, supporting the production of treatments for chronic diseases like obesity and type 2 diabetes.

Who is the new Executive Vice President of Global Quality at Eli Lilly?

Melissa Seymour has been appointed as the new Executive Vice President of Global Quality, effective July 22, 2024.

What are some recent clinical trial results shared by Eli Lilly?

Eli Lilly shared positive results from trials for insulin efsitora alfa, Verzenio, Retevmo, olomorasib, and imlunestrant, showcasing their advancements in treatments for diabetes and cancer.

In how many countries does Eli Lilly operate?

Eli Lilly operates in 18 countries and its products are sold in approximately 125 countries.

What is the significance of Eli Lilly's recent investment in Lebanon, Indiana?

The investment will enhance production capacity for essential treatments like Zepbound and Mounjaro, aiming to meet the growing demand for these medicines.

What is the focus of Eli Lilly's ongoing research and development?

Eli Lilly's R&D focuses on innovative solutions for diabetes care, obesity, Alzheimer's disease, immune disorders, and cancer.

What are some common side effects of Eli Lilly's product Mounjaro?

Common side effects of Mounjaro include nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and stomach pain.

Stock LLY logo
Eli Lilly & Co.

NYSE:LLY

LLY Rankings

#12 Ranked by Market Cap
#1941 Ranked by Dividends

LLY Stock Data

713.43B
950.41M
0.15%
83.46%
0.64%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
INDIANAPOLIS